Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this pilot study is to examine the feasibility and safety of performing a larger trial to assess outcomes following treatment of meconium aspiration syndrome with surfactant lavage compared to bolus surfactant. Specifically, we will determine if surfactant lavage results in a more rapid improvement in physiologic outcomes (e.g. pulmonary compliance), as well as clinical outcomes (e.g. length of time on mechanical ventilation).
| Condition | Intervention | Phase |
|---|---|---|
|
Meconium Aspiration Syndrome |
Drug: Bovine Lipid Extract Surfactant (administered by lavage) Drug: Bovine Lipid Extract Surfactant (administered by bolus) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration |
- % change in oxygenation indices from baseline to 1 and 6 h following treatment
- % change in dynamic pulmonary compliance from baseline to 1 and 6 h following treatment
- % change in pulmonary artery pressure from baseline to 1 and 6 h following treatment
- measures of efficacy of ventilation and oxygenation at 1 h and 6 h following treatment
- cardiac function by echocardiography at 6 hours following treatment
- % change in oxygenation indices, dynamic pulmonary compliance and pulmonary vascular resistance from baseline to 12, 24 and 48 h following treatment
- measures of efficiency of ventilation and oxygenation at 12, 24 and 48 h following treatment
- duration of mechanical ventilation, defined as the cumulative time of mechanical ventilation
- length of time on CPAP
- length of time with oxygen supplementation
- length of time on inotropes and maximum inotropic score.
- need for and length of use of NO
- need for and length of use of ECMO
- time to full enteral feeds
- attainment of exit criteria
- development of significant pulmonary hemorrhage
- development of significant intracranial hemorrhage
- development of tension pneumothorax requiring drainage
- need for repeat surfactant
- length of stay in a level III NICU
- mortality
| Estimated Enrollment: | 20 |
| Study Start Date: | April 2006 |
Meconium-stained amniotic fluid occurs in about 5 to 20% of all births in the United States, with meconium aspiration syndrome occuring in approximately 5% of these infants. In this disease process, meconium is believed to mechanically obstruct the airways, causing a chemical pneumonitis and inactivate surfactant. Approximately one-third of these babies need mechanical ventilation and approximately 5% die. Since 1990 surfactant has been the standard of care for treatment of respiratory distress syndrome. Pulmonary compliance and gas exchange often improve rapidly after administration of surfactant. Its use has led to significantly reduced mortality rates and improved short-term respiratory function. There is evidence to support its use in other neonatal respiratory disorders where there is dysfunction or inactivation of surfactant. Its use in meconium aspiration syndrome is the most well-studied alternate use to date. The Canadian Pediatric Society's (2005) position statement recommends that infants with meconium aspiration syndrome who are intubated and require more than 50% oxygen should receive exogenous surfactant therapy.
Studies in both animals and humans suggest that surfactant helps in meconium aspiration, either administered as a bolus or as a lavage. There have been no trials to date comparing the efficacy of surfactant lavage to bolus surfactant in human neonates with meconium aspiration or examining the physiologic effects of surfactant, given as either a bolus or lavage, in the treatment of meconium aspiration syndrome. This study will assess the relative efficacy of these two methods of administering surfactant and their effect on physiologic and clinical outcomes.
Eligibility| Ages Eligible for Study: | up to 24 Hours |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- infants ≥ 36 weeks gestational age with evidence of meconium aspiration syndrome
- respiratory support (ventilator or CPAP) within 6 h of birth
- enrolment within 24 h of birth
- significant difficulty with oxygenation, as indicated by an oxygenation index (OI) > 15, where OI = (FiO2 x MAP) / PaO2 and MAP is the mean airway pressure
- presence of an arterial line
Exclusion Criteria:
- major congenital anomalies
- known antenatal diagnosis of significant congenital heart disease (diagnosis other than patent foramen ovale, patent ductus arteriosus or small ventricular septal defect)
- infants with a maternal history of oligohydramnios and physical features consistent with the diagnosis
- surfactant administration prior to enrolment
- hemodynamic instability defined as intractable hypotension on more than 2 inotropes
- significant pulmonary hemorrhage, defined as pulmonary hemorrhage in association with a 30% (absolute) increase in FiO2 and radiologic changes consistent with pulmonary hemorrhage
- significant intracranial hemorrhage, defined as a unilateral or bilateral Grade III or IV intraventricular hemorrhage or a large intracranial, non-intraventricular hemorrhage
- significant illness meeting ECMO criteria with an OI > 40
- infants in whom withdrawal of intensive care is likely
Contacts and Locations| Contact: Patrick McNamara, MD | 416-813-5773 | patrick.mcnamara@sickkids.ca |
| Canada, Ontario | |
| The Hospital for Sick Children | Recruiting |
| Toronto, Ontario, Canada, M5G 1X8 | |
| Contact: Patrick McNamara, MD 416 813 5773 patrick.mcnamara@sickkids.ca | |
| Principal Investigator: Patrick McNamara, MD | |
| Sub-Investigator: Simone Vaz, MD | |
| Sub-Investigator: Hilary Whyte, MD | |
| Sub-Investigator: Jaques Belik, MD | |
| Principal Investigator: | Patrick McNamara, MD | The Hospital for Sick Children |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00312507 History of Changes |
| Other Study ID Numbers: | 1000007730 |
| Study First Received: | April 6, 2006 |
| Last Updated: | October 16, 2006 |
| Health Authority: | Canada: Health Canada |
Keywords provided by The Hospital for Sick Children:
|
Meconium Aspiration Syndrome Surfactant Bronchoalveolar Lavage newborns |
Additional relevant MeSH terms:
|
Meconium Aspiration Syndrome Lung Injury Lung Diseases Respiratory Tract Diseases Respiration Disorders Fetal Diseases |
Pregnancy Complications Infant, Newborn, Diseases Pulmonary Surfactants Respiratory System Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013